5 Result(s)
-
Article
Open AccessSecondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poo...
-
Article
Open AccessAcid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies
Despite several plausible biological mechanisms linking proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) with colorectal tumorigenesis, their association with risk of colorectal cancer (CRC) h...
-
Article
Open AccessFamily history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk
Individuals with a family history of cancer may be at increased risk of pancreatic cancer. Ashkenazi Jewish (AJ) individuals carry increased risk for pancreatic cancer and other cancer types.
-
Article
Open AccessLymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival
Few studies have simultaneously assessed the prognostic value of the multiple classification systems for lymph node (LN) metastases in resected pancreatic ductal adenocarcinoma (PDAC).
-
Article
Open AccessInfluence of dietary insulin scores on survival in colorectal cancer patients
Although hyperinsulinemia is hypothesised to be involved in colorectal carcinogenesis, it remains unclear whether a diet inducing an elevated insulin response influences colorectal cancer (CRC) survival.
